Anti-NMDA Receptor EncephalitisNCT06915103
A Case Report of NMDAR Encephalopathy
An observational study of Anti-NMDA Receptor Encephalitis and Mature Teratoma, run by Mayo Clinic at 1 site in United States.
Trial summary
This case illustrates the clinical, radiologic, and histopathologic features of Anti-NMDAR encephalitis and underscores the importance of MRI in detecting ovarian teratomas when pelvic ultrasound is inconclusive. Read more about this study
- Who is it for?
- Ages 34 to 34 years, women only
- Conditions the study is for
- Anti-NMDA Receptor Encephalitis, Mature Teratoma, Paraneoplastic Syndromes
- What is being tested?
- Magnetic Resonance Imaging (MRI) and Salpingo-oophorectomy
- Type of treatment
- Surgery or procedure
- How many people
- 1 participants
- Where
- 1 siteUnited States
- Study dates
- 20 Jun 2024to 19 Dec 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 34 to 34 years
- Women only
- No healthy volunteers
- Adult
Study population: Female patient presenting to emergency department with acute psychosis, characterized by alternating episodes of catatonia and mania, regressive speech, and inappropriate behaviors.
Who may be able to join
- Suspected Anti-NMDA Encephalitis
Who cannot join
- Inability to consent
Trial locations and contacts
1 site in 1 country.
About this study
This case illustrates the clinical, radiologic, and histopathologic features of Anti-NMDAR encephalitis and underscores the importance of MRI in detecting ovarian teratomas when pelvic ultrasound is inconclusive.
- Being tested
- Magnetic Resonance Imaging (MRI), Salpingo-oophorectomy
- Keywords
- Magnetic Resonance, Gynecologic Surgery
- Medical subject headings
- Anti-N-Methyl-D-Aspartate Receptor Encephalitis, Dermoid Cyst, Paraneoplastic Syndromes
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Magnetic Resonance Imaging (MRI)Diagnostic test
A pelvic MRI with and without contrast was performed for evaluation of the ovary.
Salpingo-oophorectomyProcedure or surgery
Salpingo-oophorectomy procedure was performed on the left ovary.
What is being measured
The primary outcome is the main question the study is designed to answer.
Anti-NMDA Encephalitis
Diagnosis of Anti-NMDA Encephalitis based on pelvic MRI
Measured: 1 week
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Apr 2025
- Study start20 Jun 2024
- Primary completion8 Jul 2024
- Study completion19 Dec 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Anti-NMDA Receptor EncephalitisStudies of the same condition, open and under way.
- More trials run by Mayo ClinicThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 1 participants (actual)
Sponsor and investigators
- Lead sponsor
- Mayo Clinic
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Tri Dinh, Mayo Clinic
- Investigators
- Tri A. Dinh, MD, Principal investigator, Mayo Clinic
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06915103
- Sponsor's protocol ID
- D-25-00229R1
- Status last verified
- Apr 2025
- First submitted
- 1 Apr 2025
- Last updated
- 8 Apr 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Case Report of NMDAR Encephalopathy
- ClinicalTrials.gov ID
- NCT06915103
- Acronym / sponsor ID
- D-25-00229R1
- Keywords
- Magnetic Resonance, Gynecologic Surgery
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1 participants (actual)
- Lead sponsor
- Mayo ClinicUniversity, hospital or other
- Study start
- 20 Jun 2024 (actual)
- Primary completion
- 8 Jul 2024 (actual)
- Study completion
- 19 Dec 2024 (actual)
- First posted
- 8 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This case illustrates the clinical, radiologic, and histopathologic features of Anti-NMDAR encephalitis and underscores the importance of MRI in detecting ovarian teratomas when pelvic ultrasound is inconclusive.
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
Who may qualify
- Ages
- 34 to 34 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- Female patient presenting to emergency department with acute psychosis, characterized by alternating episodes of catatonia and mania, regressive speech, and inappropriate behaviors.
Key inclusion criteria (1 listed)
- Suspected Anti-NMDA Encephalitis
Key exclusion criteria (1 listed)
- Inability to consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Magnetic Resonance Imaging (MRI)A pelvic MRI with and without contrast was performed for evaluation of the ovary. | Diagnostic test | – |
| Salpingo-oophorectomySalpingo-oophorectomy procedure was performed on the left ovary. | Procedure or surgery | – |
Primary outcome
Anti-NMDA Encephalitis
Time frame: 1 week
Diagnosis of Anti-NMDA Encephalitis based on pelvic MRI
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Apr 2025.
- Individual participant dataSharing planned: No
Related trials for Anti-NMDA Receptor Encephalitis
RecruitingPhase 2
A Study in Participants With Anti-NMDAR Encephalitis and Anti-NMDAR Autoantibody-Associated Psychiatric Disease
Anti-N-methyl-D-aspartate Receptor (NMDAR) Encephalitis (ANRE), Anti-N-methyl-D-aspartate Receptor (NMDAR) Antibody-associated Psychiatric Disease
Active, not recruitingPhase 3
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis
Not yet recruitingObservational study
Clinical Evaluation of a Novel DAB Chromogenic Tissue-Based Assay for Detecting Anti-GABABR Antibodies
Autoimmune Encephalitis, Anti-NMDAR Encephalitis
RecruitingPhase 2
Efgartigimod in Anti-NMDA Receptor Encephalitis.
Encephalitis Autoimmune
RecruitingPhase 3
Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis
Anti-N-Methyl-D-Aspartate Receptor Encephalitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Tri A. Dinh, MD principal investigator
Mayo Clinic
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Anti-NMDA Receptor Encephalitis and Mature Teratoma, run by Mayo Clinic at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Anti-NMDA Encephalitis (time frame: 1 week). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Apr 2025.